



Martin Risch

Contact

Martin Risch

Publications (9)

Purde M, Niederer R, Wagner N, Diem S, Berner F, Hasan Ali O, Hillmann D, Bergamin I, Jörger M, Risch M, Niederhauser C, Lenz T, Früh M, Risch L, Semela D, Flatz L. Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients. *J Cancer Res Clin Oncol* 2021; 148:647-656.

Weber M, Imperiali M, Salimi Y, Fleisch F, Cusini A, Heer S, Renz H, Paprotny M, Kohler P, Vernazza P, Risch L, Bodmer T, Egli K, Risch M, Thiel S, Grossmann K, Nigg S, Wohlwend N, Lung T, Hillmann D, Ritzler M, Ferrara F, Bigler S, Kahlert C. Characteristics of Three Different Chemiluminescence Assays for Testing for SARS-CoV-2 Antibodies. *Dis Markers* 2021; 2021:8810196.

Schaffner A, Bodmer T, Imperiali M, Renz H, Kohler P, Vernazza P, Kahlert C, Twerenbold R, Paprotny M, Conen D, Bigler S, Hillmann D, Lung T, Risch L, Aeschbacher S, Risch C, Weber M, Thiel S, Jüngert K, Pichler M, Grossmann K, Wohlwend N, Risch M. Characterization of a Pan-Immunoglobulin Assay Quantifying Antibodies Directed against the Receptor Binding Domain of the SARS-CoV-2 S1-Subunit of the Spike Protein: A Population-Based Study. *J Clin Med* 2020; 9

Risch M, Imperiali M, Salimi Y, Fleisch F, Cusini A, Renz H, Kohler P, Vernazza P, Kahlert C, Paprotny M, Bodmer T, Egli K, Weber M, Thiel S, Grossmann K, Wohlwend N, Lung T, Hillmann D, Ritzler M, Ferrara F, Bigler S, Risch L. Temporal Course of SARS-CoV-2 Antibody Positivity in Patients with COVID-19 following the First Clinical Presentation. *Biomed Res Int* 2020; 2020:9878453.

Thiel S, Copeland S, Karajan T, Cusini A, Fleisch F, Kahlert C, Vernazza P, Risch M, Ritzler M, Hillmann D, Lung T, Wohlwend N, Risch L, Weber M, Paprotny M. Flattening the curve in 52 days: characterisation of the COVID-19 pandemic in the Principality of Liechtenstein - an observational study. *Swiss Med Wkly* 2020; 150:w20361.

Baron R, Bodmer T, Imperiali M, Heer S, Renz H, Flatz L, Kohler P, Vernazza P, Kahlert C, Paprotny M, Ferrara F, Egli K, Risch L, Weber M, Thiel S, Grossmann K, Wohlwend N, Lung T, Hillmann D, Ritzler M, Bigler S, Risch M. Frequency of serological non-responders and false-negative RT-PCR results in SARS-CoV-2 testing: a population-based study. *Clin Chem Lab Med* 2020; 58:2131-2140.

Kovac M, Egli K, Imperiali M, Heer S, Salimi Y, Renz H, Kohler P, Vernazza P, Kahlert C, Paprotny M, Bodmer T, Ferrara F, Risch L, Thiel S, Weber M, Grossmann K, Wohlwend N, Lung T, Hillmann D, Ritzler M, Bigler S, Risch M. EDTA-Anticoagulated Whole Blood for SARS-CoV-2 Antibody Testing by Electrochemiluminescence Immunoassay (ECLIA) and Enzyme-Linked Immunosorbent Assay (ELISA). *Diagnostics (Basel)* 2020; 10

Diem S, Risch M, Recher M, Risch L, Dummer R, Levesque M, Mangana J, Hillmann D, Niederer R, Berner F, Ali O, Bomze D, Fässler M, Flatz L. Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment. *J Immunother* 2019; 42:89-93.

Fässler M, Jörger M, Recher M, Risch L, Güsewell S, Risch M, Speiser D, Ludwig B, Levesque M, Dummer R, Siano M, Krollik M, Diem S, Mangana J, Hasan Ali O, Berner F, Bomze D, Ring S, Niederer R, Gil Cruz C, Pérez Shibayama C, Flatz L. Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients. *J Immunother Cancer* 2019; 7:50.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch